Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.68 USD | -6.54% | -5.57% | -5.16% |
May. 14 | Transcript : VolitionRx Limited, Q1 2024 Earnings Call, May 14, 2024 | |
May. 13 | VolitionRx Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.16% | 60.26M | C | ||
-36.44% | 9.2B | A- | ||
-3.29% | 3.12B | C | ||
+19.31% | 2.8B | D+ | ||
-18.71% | 2.07B | - | B- | |
-22.03% | 1.59B | C+ | ||
+64.58% | 1.44B | B- | ||
+34.58% | 830M | C- | ||
-7.42% | 724M | C+ | ||
-25.51% | 507M | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VNRX Stock
- Ratings VolitionRx Limited